Introduction: The global disease burden of major depressive disorder urgently requires prevention in high-risk individuals, such as recently discovered insomnia subtypes. Previous studies targeting ...insomnia with fully automated eHealth interventions to prevent depression are inconclusive: dropout was high and likely biased, and depressive symptoms in untreated participants on average improved rather than worsened. Objective: This randomized controlled trial aimed to efficiently prevent the worsening of depressive symptoms by selecting insomnia subtypes at high risk of depression for internet-based circadian rhythm support (CRS), cognitive behavioral therapy for insomnia (CBT-I), or their combination (CBT-I+CRS), with online therapist guidance to promote adherence. Methods: Participants with an insomnia disorder subtype conveying an increased risk of depression (n = 132) were randomized to no treatment (NT), CRS, CBT-I, or CBT-I+CRS. The Inventory of Depressive Symptomatology – Self Report (IDS-SR) was self-administered at baseline and at four follow-ups spanning 1 year. Results: Without treatment, depressive symptoms indeed worsened (d = 0.28, p = 0.041) in high-risk insomnia, but not in a reference group with low-risk insomnia. Therapist-guided CBT-I and CBT-I+CRS reduced IDS-SR ratings across all follow-up assessments (respectively, d = –0.80, p = 0.001; d = –0.95, p < 0.001). Only CBT-I+CRS reduced the 1-year incidence of clinically meaningful worsening (p = 0.002). Dropout during therapist-guided interventions was very low (8%) compared to previous automated interventions (57–62%). Conclusions: The findings tentatively suggest that the efficiency of population-wide preventive strategies could benefit from the possibility to select insomnia subtypes at high risk of developing depression for therapist-guided digital CBT-I+CRS. This treatment may provide effective long-term prevention of worsening of depressive symptoms. Trial registration: the Netherlands Trial Register (NL7359).
A head-to-head comparison was performed between vascular endothelial growth factor blockade and laser for treatment of diabetic macular edema (DME).
Two similarly designed, double-masked, randomized, ...phase 3 trials, VISTA(DME) and VIVID(DME).
We included 872 patients (eyes) with type 1 or 2 diabetes mellitus who presented with DME with central involvement.
Eyes received either intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 initial monthly doses (2q8), or macular laser photocoagulation.
The primary efficacy endpoint was the change from baseline in best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 52. Secondary efficacy endpoints at week 52 included the proportion of eyes that gained ≥ 15 letters from baseline and the mean change from baseline in central retinal thickness as determined by optical coherence tomography.
Mean BCVA gains from baseline to week 52 in the IAI 2q4 and 2q8 groups versus the laser group were 12.5 and 10.7 versus 0.2 letters (P < 0.0001) in VISTA, and 10.5 and 10.7 versus 1.2 letters (P < 0.0001) in VIVID. The corresponding proportions of eyes gaining ≥ 15 letters were 41.6% and 31.1% versus 7.8% (P < 0.0001) in VISTA, and 32.4% and 33.3% versus 9.1% (P < 0.0001) in VIVID. Similarly, mean reductions in central retinal thickness were 185.9 and 183.1 versus 73.3 μm (P < 0.0001) in VISTA, and 195.0 and 192.4 versus 66.2 μm (P < 0.0001) in VIVID. Overall incidences of ocular and nonocular adverse events and serious adverse events, including the Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events and vascular deaths, were similar across treatment groups.
At week 52, IAI demonstrated significant superiority in functional and anatomic endpoints over laser, with similar efficacy in the 2q4 and 2q8 groups despite the extended dosing interval in the 2q8 group. In general, IAI was well-tolerated.
ABSTRACT We investigate the dependence of galaxy sizes and star formation rates (SFRs) on their environment using a mass-limited sample of quiescent and star-forming galaxies with log(M*/ ) ≥ 9.5 at ...selected from the NEWFIRM medium-band Survey (NMBS). Using the Galaxy Environment Evolution Collaboration 2 spectroscopic cluster catalog and the accurate photometric redshifts from the NMBS, we select quiescent and star-forming cluster ( km s−1) galaxies within two virial radius, Rvir, intervals of 2 > Rvir > 0.5 and Rvir < 0.5. Galaxies residing outside of the 2 Rvir of both the cluster centers and the additional candidate over-densities are defined as our field sample. Galaxy structural parameters are measured from the COSMOS legacy Hubble Space Telescope/ACS F814W image. The sizes and Sérsic indices of quiescent field and cluster galaxies have the same distribution regardless of Rvir. However, cluster star-forming galaxies within 0.5 Rvir have lower mass-normalized average sizes by , and a higher fraction of Sérsic indices with , than field star-forming galaxies. The average SFRs of star-forming cluster galaxies show a trend of decreasing SFR with clustocentric radius. The mass-normalized average SFR of cluster star-forming galaxies is a factor of ( ) lower than that of star-forming galaxies in the field. While we find no significant dependence on environment for quiescent galaxies, the properties of star-forming galaxies are affected, which could be the result of environment acting on their gas content.
Photoplethysmography (PPG) signal quality as a proxy for accuracy in heart rate (HR) measurement is useful in various public health contexts, ranging from short-term clinical diagnostics to ...free-living health behavior surveillance studies that inform public health policy. Each context has a different tolerance for acceptable signal quality, and it is reductive to expect a single threshold to meet the needs across all contexts. In this study, we propose two different metrics as sliding scales of PPG signal quality and assess their association with accuracy of HR measures compared to a ground truth electrocardiogram (ECG) measurement.
We used two publicly available PPG datasets (BUT PPG and Troika) to test if our signal quality metrics could identify poor signal quality compared to gold standard visual inspection. To aid interpretation of the sliding scale metrics, we used ROC curves and Kappa values to calculate guideline cut points and evaluate agreement, respectively. We then used the Troika dataset and an original dataset of PPG data collected from the chest to examine the association between continuous metrics of signal quality and HR accuracy. PPG-based HR estimates were compared with reference HR estimates using the mean absolute error (MAE) and the root-mean-square error (RMSE). Point biserial correlations were used to examine the association between binary signal quality and HR error metrics (MAE and RMSE).
ROC analysis from the BUT PPG data revealed that the AUC was 0.758 (95% CI 0.624 to 0.892) for signal quality metrics of STD-width and 0.741 (95% CI 0.589 to 0.883) for self-consistency. There was a significant correlation between criterion poor signal quality and signal quality metrics in both Troika and originally collected data. Signal quality was highly correlated with HR accuracy (MAE and RMSE, respectively) between PPG and ground truth ECG.
This proof-of-concept work demonstrates an effective approach for assessing signal quality and demonstrates the effect of poor signal quality on HR measurement. Our continuous signal quality metrics allow estimations of uncertainties in other emergent metrics, such as energy expenditure that relies on multiple independent biometrics. This open-source approach increases the availability and applicability of our work in public health settings.
Schistosomiasis control requires multisectoral approaches including praziquantel treatment, access to safe water, sanitation and hygiene, and health education. Community input can help ensure health ...education programs are culturally appropriate to effectively direct protective behavior change. This study reports on the three-stage development of an education program for Malagasy children, with an impact evaluation on their knowledge, attitudes, and practices (KAP) related to intestinal schistosomiasis. A cross-sectional study took place in 2017 with follow-up in 2018 in the hard-to-reach Marolambo district, Madagascar. A novel schistosomiasis education program (SEP) was designed in collaboration with researchers, stakeholders, and local community and included cartoon books, games, songs, puzzles, and blackboard lessons, costing $10 USD per school. KAP questionnaires were completed by 286 children pre-SEP and 273 children post-SEP in 2017, and by 385 and 337 children pre-SEP and post-SEP, respectively, in 2018. Improvements were observed in responses to all questions between pre- and post-education answers in 2017 (53-77%, P < 0.0001) and 2018 (72-98%, P < 0.0001) and in the pre-education answers between years (53-72%, P < 0.0001). Praziquantel mass drug administration attendance improved, rising from 64% to 91% (P < 0.0001), alongside improved latrine use, from 89% to 96% (P = 0.005). This community-consulted and -engaged SEP resulted in substantial improvements in children's understanding of schistosomiasis, with improvements in praziquantel uptake and latrine use. Socioculturally tailored education programs can help gain schistosomiasis control. Continued investment in SEP will help promote the future well-being of children through increased participation in control and treatment activities.
Abstract Introduction Medical studies have shown some potential for infiltrations of liposomal bupivacaine (Exparel; Pacira Pharmaceuticals, San Diego, CA), a slow-release bupivacaine solution, to ...extend postoperative benefits of numbness/pain relief for up to several days. Because the Food and Drug Administration has approved Exparel only for infiltrations, we wanted to evaluate if it would be effective as an infiltration to control postoperative pain. The purpose of this study was to compare an infiltration of bupivacaine with liposomal bupivacaine for postoperative numbness and pain in symptomatic patients diagnosed with pulpal necrosis experiencing moderate to severe preoperative pain. Methods One hundred patients randomly received a 4.0-mL buccal infiltration of either bupivacaine or liposomal bupivacaine after endodontic debridement. For postoperative pain, patients were given ibuprofen/acetaminophen, and they could receive narcotic pain medication as an escape. Patients recorded their level of numbness, pain, and medication use the night of the appointment and over the next 5 days. Success was defined as no or mild postoperative pain and no narcotic use. Results The success rate was 29% for the liposomal group and 22% for the bupivacaine group, with no significant difference ( P = .4684) between the groups. Liposomal bupivacaine had some effect on soft tissue numbness, pain, and use of non-narcotic medications, but it was not clinically significant. There was no significant difference in the need for escape medication. Conclusions For symptomatic patients diagnosed with pulpal necrosis experiencing moderate to severe preoperative pain, a 4.0-mL infiltration of liposomal bupivacaine did not result in a statistically significant increase in postoperative success compared with an infiltration of 4.0 mL bupivacaine.
Table of Contents Preamble2647 Introduction2649 Methodology and Evidence Review2649 Organization of the GWC2649 Document Review and Approval2649 Scope of the CPG2650 Overview of ACS2650 Initial ...Evaluation and Management: Recommendations2650 Clinical Assessment and Initial Evaluation2650 Emergency Department or Outpatient Facility Presentation2650 Prognosis--Early Risk Stratification2650 Cardiac Biomarkers and the Universal Definition of Myocardial Infarction2654 Biomarkers: Diagnosis2654 Biomarkers: Prognosis2654 Discharge From the ED or Chest Pain Unit2655 Early Hospital Care: Recommendations2655 Standard Medical Therapies2655 Oxygen2655 Nitrates2655 Analgesic Therapy2655 Beta-Adrenergic Blockers2656 Calcium Channel Blockers2657 Cholesterol Management2657 Inhibitors of the Renin-Angiotensin-Aldosterone System2657 Initial Antiplatelet/Anticoagulant Therapy in Patients With Definite or Likely NSTE-ACS2657 Initial Oral and Intravenous Antiplatelet Therapy in Patients With Definite or Likely NSTE-ACS Treated With an Initial Invasive or Ischemia-Guided Strategy2657 Initial Parenteral Anticoagulant Therapy in Patients With Definite NSTE-ACS2659 Ischemia-Guided Strategy Versus Early Invasive Strategies2659 Early Invasive and Ischemia-Guided Strategies2659 Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS2661 Myocardial Revascularization: Recommendations2661 PCI--General Considerations2661 PCI--Oral and Intravenous Antiplatelet Agents2661 PCI--GP IIb/IIIa Inhibitors2662 Anticoagulant Therapy in Patients Undergoing PCI2663 Timing of Urgent Coronary Artery Bypass Graft in Patients With NSTE-ACS in Relation to Use of Antiplatelet Agents2663 Late Hospital Care, Hospital Discharge, and Posthospital Discharge Care: Recommendations2663 Medical Regimen and Use of Medications at Discharge2663 Late Hospital and Posthospital Oral Antiplatelet Therapy2664 Combined Oral Anticoagulant Therapy and Antiplatelet Therapy in Patients With NSTE-ACS2664 Risk Reduction Strategies for Secondary Prevention2664 Plan of Care for Patients With NSTE-ACS2665 Special Patient Groups: Recommendations2665 NSTE-ACS in Older Patients2665 Heart Failure and Cardiogenic Shock2665 Diabetes Mellitus2667 Post-CABG2668 Perioperative NSTE-ACS Related to Noncardiac Surgery2668 Chronic Kidney Disease2668 Women2668 Anemia, Bleeding, and Transfusion2668 Cocaine and Methamphetamine Users2668 Vasospastic (Prinzmetal) Angina2668 ACS With Angiographically Normal Coronary Arteries2669 Stress (Takotsubo) Cardiomyopathy2669 Quality of Care and Outcomes for ACS--Use of Performance Measures and Registries: Recommendation2669 Summary and Evidence Gaps2669 References2670 Appendix 1 Author Relationships With Industry and Other Entities (Relevant)2680 Appendix 2 Reviewer Relationships With Industry and Other Entities (Relevant)2683 Preamble The American College of Cardiology (ACC) and the American Heart Association (AHA) are committed to the prevention and management of cardiovascular diseases through professional education and research for clinicians, providers, and patients. Since 1980, the ACC and AHA have shared a responsibility to translate scientific evidence into clinical practice guidelines (CPGs) with recommendations to standardize and improve cardiovascular health.
Abstract
We present the velocity dispersion measurements of four massive ∼10
11
M
⊙
quiescent galaxies at 3.2 <
z
< 3.7 based on deep
H
and
K
-band spectra using the Keck/MOSFIRE near-infrared ...spectrograph. We find high velocity dispersions of order
σ
e
∼250 km s
−1
based on strong Balmer absorption lines, and we combine these with size measurements based on HST/WFC3 F160W imaging to infer dynamical masses. The velocity dispersions are broadly consistent with the high stellar masses and small sizes. Together with evidence for quiescent stellar populations, the spectra confirm the existence of a population of massive galaxies that formed rapidly and quenched in the early universe
z
> 4. Investigating the evolution at constant velocity dispersion between
z
∼3.5 and
z
∼2, we find a large increase in effective radius 0.35 ± 0.12 dex and in dynamical-to-stellar mass ratio
of 0.33 ± 0.08 dex, with low expected contribution from dark matter. The dynamical masses for our
z
∼3.5 sample are consistent with the stellar masses for a Chabrier initial mass function (IMF), with the ratio
dex suggesting an IMF lighter than Salpeter may be common for massive quiescent galaxies at
z
> 3. This is surprising in light of the Salpeter or heavier IMFs found for high velocity dispersion galaxies at
z
∼2 and cores of present-day ellipticals, which these galaxies are thought to evolve into. Future imaging and spectroscopic observations with resolved kinematics using the upcoming James Webb Space Telescope could rule out potential systematics from rotation and confirm these results.
Background Delirium is a common complication after cardiac surgical procedures and is associated with increased morbidity and mortality. However, whether rigorously assessed postoperative delirium is ...associated with an increased length of stay in the intensive care unit (LOS-ICU), length of stay (LOS), and hospital charges is not clear. Methods Patients (n = 66) undergoing coronary artery bypass or valve operations, or both, were enrolled in a nested cohort study. Rigorous delirium assessments were conducted using the Confusion Assessment Method. LOS-ICU and LOS were obtained from the medical record, and hospital charges were obtained from administrative data reported to the state. Because of the skewed distribution of outcome variables, outcomes were compared using rank-sum tests, as well as median regression incorporating propensity scores. Results Patients who developed delirium (56%) versus no delirium (43%) had increased median LOS-ICU (75.6 hours interquartile range (IQR): 43.6 to 136.8 vs. 29.7 hours IQR: 21.7 to 46.0; p = 0.002), increased median LOS (9 days IQR: 6 to 16 vs. 7 days IQR: 5 to 8; p = 0.006), and increased median hospital charges ($51,805 IQR: $44,041 to $80,238 vs. $41,576 IQR: $35,748 to $43,660; p = 0.002). In propensity score models adjusted for patient-related and surgical characteristics and complications, the results for LOS-ICU and cost remained highly significant, although the results for LOS were attenuated on the basis of the specific statistical model. Increased severity of delirium was associated with both increased LOS-ICU and increased charges in a dose-response manner. Conclusions Delirium after cardiac surgical procedures is independently associated with both increased LOS-ICU and higher hospital charges. Because delirium is potentially preventable, targeted delirium-prevention protocols for high-risk patients may represent an important strategy for quality improvement.
The AzTEC mm-wavelength camera Wilson, G. W.; Austermann, J. E.; Perera, T. A. ...
Monthly notices of the Royal Astronomical Society,
20/May , Letnik:
386, Številka:
2
Journal Article
Recenzirano
Odprti dostop
AzTEC is a mm-wavelength bolometric camera utilizing 144 silicon nitride micromesh detectors. Here, we describe the AzTEC instrument architecture and its use as an astronomical instrument. We report ...on several performance metrics measured during a three-month observing campaign at the James Clerk Maxwell Telescope and conclude with our plans for AzTEC as a facility instrument on the Large Millimetre Telescope.
PDF
